HKD 3.4
(3.66%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -3.51 Billion CNY | -70.75% |
2022 | -384.33 Million CNY | 34.83% |
2021 | -589.69 Million CNY | -217.16% |
2020 | 503.34 Million CNY | 212.48% |
2019 | 161.08 Million CNY | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -142.08 Million CNY | 95.56% |
2023 Q2 | -310.11 Million CNY | -1.28% |
2023 Q4 | -3.2 Billion CNY | -932.59% |
2023 FY | -656.22 Million CNY | -70.75% |
2022 Q4 | -306.17 Million CNY | 0.0% |
2022 FY | -384.33 Million CNY | 34.83% |
2021 FY | -589.69 Million CNY | -217.16% |
2020 FY | 503.34 Million CNY | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Uni-Bio Science Group Limited | 67.76 Million HKD | 5282.843% |
CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 491.146% |